Liposome-delivered 131I-labelled Zn(II)-phthalocyanine as a radiodiagnostic agent for tumours.

Abstract

131I-Zn(II)-phthalocyanine (ZnPc) incorporated into unilamellar liposomes has been systemically injected to mice bearing a transplanted MS-2 fibrosarcoma. Biodistribution studies show that the pharmacokinetic behaviour of 131I-ZnPc is very similar to that defined for the parent molecule ZnPc including a serum half-life of ca. 12 h, a high recovery from liver and spleen and minimal accumulation in kidney and brain. The most important pharmacokinetic parameter is represented by the high tumour/ muscle ratio of 131I-ZnPc concentration (ca. 9 at 24 h post-injection). These results suggest the possible use of the radiolabelled derivative for a real-time non-invasive monitoring of the ZnPc concentration in the tumour and peritumoural tissue during photodynamic therapy.

• Authors: L Polo, A Segalla, G Jori, G Bocchiotti, G Verna, R Franceschini, R Mosca, P G De Filippi
• Journal: Cancer letters (Cancer Lett) Vol. 109 Issue 1-2 Pg. 57-61 (Dec 03 1996) ISSN: 0304-3835 [Print] Ireland
• PMID: 9020903 (Publication Type: Journal Article)

Chemical References

• Indoles
• Iodine Radioisotopes
• Isoindoles
• Liposomes
• Organometallic Compounds
• Zinc Compounds
• Zn(II)-phthalocyanine

Topics

• Animals
• Fibrosarcoma (diagnostic imaging, metabolism)
• Indoles (pharmacokinetics)
• Iodine Radioisotopes (pharmacokinetics)
• Isoindoles
• Liposomes
• Mice
• Mice, Inbred BALB C
• Muscles (metabolism)
• Organometallic Compounds (pharmacokinetics)
• Radionuclide Imaging
• Time Factors
• Tissue Distribution
• Tumor Cells, Cultured
• Zinc Compounds